The c-Met receptor: Implication for targeted therapies in colorectal cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The c-Met receptor: Implication for targeted therapies in colorectal cancer
Authors
Keywords
-
Journal
TUMOR BIOLOGY
Volume 39, Issue 5, Pages 101042831769911
Publisher
SAGE Publications
Online
2017-05-01
DOI
10.1177/1010428317699118
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer
- (2016) Zhenfu Han et al. ChemMedChem
- Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs
- (2016) Jin Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Biomarker development in MET-targeted therapy
- (2016) Yanni Zhang et al. Oncotarget
- c-Met targeting in advanced gastric cancer: An open challenge
- (2015) Luigi Marano et al. CANCER LETTERS
- Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti-angiogenesis activity in a preclinical cancer model
- (2015) Youya Nakazawa et al. CANCER SCIENCE
- LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET
- (2015) Belén Mezquita et al. MOLECULAR CARCINOGENESIS
- High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis
- (2015) HeLi Gao et al. TUMOR BIOLOGY
- Prognostic value of c-Met in colorectal cancer: A meta-analysis
- (2015) Yan Liu WORLD JOURNAL OF GASTROENTEROLOGY
- Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets
- (2015) Katherine Chang et al. Oncotarget
- Abstract 728: AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models
- (2015) Paul E. Hughes et al. CANCER RESEARCH
- Discovery of Fully Human Anti-MET Monoclonal Antibodies with Antitumor Activity against Colon Cancer Tumor Models In Vivo
- (2015) Edward Htun van der Horst et al. NEOPLASIA
- Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial
- (2014) Kelong Han et al. AAPS Journal
- MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells
- (2014) C. Boccaccio et al. CANCER RESEARCH
- MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors
- (2014) Paolo Luraghi et al. CANCER RESEARCH
- Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
- (2014) Takayuki Nakagawa et al. CANCER SCIENCE
- Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model
- (2014) Eun-Kee Song et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting the oncogenic Met receptor by antibodies and gene therapy
- (2014) E Vigna et al. ONCOGENE
- Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status
- (2014) Jeeyun Lee et al. PLoS One
- Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
- (2014) Hui-Yan Luo WORLD JOURNAL OF GASTROENTEROLOGY
- MACC1 Is Related to Colorectal Cancer Initiation and Early-Stage Invasive Growth
- (2013) Bing Ren et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
- (2013) Lixia Ju et al. Cancer Cell International
- EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis
- (2013) J. L. Breindel et al. CANCER RESEARCH
- Increased TGF- as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells
- (2013) T. Troiani et al. CLINICAL CANCER RESEARCH
- Ligand-independent activation of MET through IGF-1/IGF-1R signaling
- (2013) Andreas Varkaris et al. INTERNATIONAL JOURNAL OF CANCER
- Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion
- (2013) Lin Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Role of cMET in the Development and Progression of Colorectal Cancer
- (2013) Juan Pérez-Vargas et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities
- (2013) Y. Awazu et al. MOLECULAR CANCER THERAPEUTICS
- Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2
- (2013) Anna C. Navis et al. PLoS One
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines
- (2013) S Zhao et al. Oncogenesis
- Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations
- (2013) A. Ruth He et al. Therapeutic Advances in Gastroenterology
- Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer
- (2012) Shinji Takeuchi et al. AMERICAN JOURNAL OF PATHOLOGY
- Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients
- (2012) Massimiliano Berretta et al. ANTI-CANCER DRUGS
- Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474
- (2012) Monika Klotz et al. BIOMARKERS
- The transcriptional landscape and mutational profile of lung adenocarcinoma
- (2012) J.-S. Seo et al. GENOME RESEARCH
- HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells
- (2012) ATSUSHI MATSUMURA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
- (2012) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR–TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment
- (2012) Wolfram Brugger et al. LUNG CANCER
- miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation
- (2012) J. F. Reid et al. MOLECULAR CANCER RESEARCH
- Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor
- (2012) H. Y. Zou et al. MOLECULAR CANCER THERAPEUTICS
- Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
- (2012) Alex Kentsis et al. NATURE MEDICINE
- The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
- (2011) Weon-Kyoo You et al. BMB Reports
- Differential roles of trans-phosphorylated EGFR, HER2, HER3 and RET as heterodimerisation partners of MET in lung cancer with MET amplification
- (2011) J Tanizaki et al. BRITISH JOURNAL OF CANCER
- Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction
- (2011) S. Benvenuti et al. CANCER RESEARCH
- MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents
- (2011) W. Fan et al. CANCER RESEARCH
- MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer
- (2011) C. Migliore et al. CLINICAL CANCER RESEARCH
- Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?
- (2011) Alessandro Inno et al. Clinical Colorectal Cancer
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas
- (2011) Koji Tsuta et al. Journal of Thoracic Oncology
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- HGF-independent potentiation of EGFR action by c-Met
- (2011) A M Dulak et al. ONCOGENE
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy
- (2010) Ming-Hai Wang et al. ACTA PHARMACOLOGICA SINICA
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
- (2010) D. Liska et al. CLINICAL CANCER RESEARCH
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
- (2010) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- Targeting the HGF/Met signalling pathway in cancer
- (2010) Fabiola Cecchi et al. EUROPEAN JOURNAL OF CANCER
- TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation
- (2010) W. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Novel Agents on the Horizon for Cancer Therapy
- (2009) W. W. Ma et al. CA-A CANCER JOURNAL FOR CLINICIANS
- RASSF1A Mediates p21Cip1/Waf1-Dependent Cell Cycle Arrest and Senescence through Modulation of the Raf-MEK-ERK Pathway and Inhibition of Akt
- (2009) S. Thaler et al. CANCER RESEARCH
- E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models
- (2009) Takayuki Nakagawa et al. CANCER SCIENCE
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Colon cancer metastasis: MACC1 and Met as metastatic pacemakers
- (2009) Franziska Arlt et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Decorin is a novel antagonistic ligand of the Met receptor
- (2009) Silvia Goldoni et al. JOURNAL OF CELL BIOLOGY
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
- (2009) Andrea Sartore-Bianchi et al. PLoS One
- Developing c-MET pathway inhibitors for cancer therapy: progress and challenges
- (2009) Xiangdong Liu et al. TRENDS IN MOLECULAR MEDICINE
- The Met tyrosine kinase receptor in development and cancer
- (2008) Alessandra Gentile et al. CANCER AND METASTASIS REVIEWS
- MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
- (2008) H. Jin et al. CANCER RESEARCH
- The Prognostic Significance of RON and MET Receptor Coexpression in Patients with Colorectal Cancer
- (2008) Chung-Ta Lee et al. DISEASES OF THE COLON & RECTUM
- MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis
- (2008) Ulrike Stein et al. NATURE MEDICINE
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
- Oncogenes and Cancer
- (2008) Carlo M. Croce NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation